Lymphopenia News and Research

RSS
Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Combination of perifosine and temsirolimus shows promise against malignant glioma

Combination of perifosine and temsirolimus shows promise against malignant glioma

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Crizotinib may be effective treatment option for NSCLC subtype

Crizotinib may be effective treatment option for NSCLC subtype

Specialist referral unearths wide spectrum of adult primary immune deficiencies

Specialist referral unearths wide spectrum of adult primary immune deficiencies